ozekibart (INBRX-109)

About Inhibrx Biosciences

Inhibrx Biosciences is a public, clinical-stage biotech focused on developing differentiated biologics for high-need oncology indications. Its core innovation is a versatile single-domain antibody (sdAb) platform that enables the creation of multi-valent, conditionally active molecules with potential advantages over conventional antibodies. The company's strategy centers on advancing its two lead clinical assets, a tetravalent DR5 agonist for sarcoma and a hexavalent OX40 agonist for solid tumors, while leveraging its lean, protein-engineering expertise to create future pipeline candidates.

Therapeutic Areas